Type of Posting: General Announcement
Posting Date: 28-Apr-2023
USP has changed how redesign-only Documentary Standards appear in the online platform. A redesign-only revision indicates that the file has been updated to the current USP style with no additional content changes or revisions that impact the Standards. Previously, the official date of these files would be unchanged from their original publication. Now, each file will be published with a “To Be Official” status and will become official six months after posting.
The following statement will be included in each redesign-only file: “This monograph has been updated to current USP style. No revisions or changes to tests have been made.”
The following list includes impacted Documentary Standards:
- AMPHOTERICIN B FOR INJECTION – Posted June 1, 2023; Official Dec 1, 2023
- CHLORTETRACYCLINE AND SULFAMETHAZINE BISULFATES SOLUBLE POWDER – Posted June 1, 2023; Official Dec 1, 2023
- CHLORTETRACYCLINE HYDROCHLORIDE OINTMENT – Posted June 1, 2023; Official Dec 1, 2023
- CHLORTETRACYCLINE HYDROCHLORIDE SOLUBLE POWDER – Posted June 1, 2023; Official Dec 1, 2023
- PROCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION – Posted June 1, 2022; Official December 1, 2022
- PROCAINE HYDROCHLORIDE INJECTION – Posted June 1, 2022; Official December 1, 2022
- TOLNAFTATE GEL – Posted June 1, 2023; Official Dec 1, 2023
Should you have any questions, please contact Marian Lydon (myh@usp.org).
CN-23-050-00